{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:50Z","timestamp":1794047450521,"version":"4.8.0"},"reference-count":8,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"4","license":[{"start":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T00:00:00Z","timestamp":1696464000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"DOI":"10.3324\/haematol.2023.283563","type":"journal-article","created":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T03:05:45Z","timestamp":1696475145000},"page":"1301-1305","source":"Crossref","is-referenced-by-count":0,"title":["A patient with minimal myeloma treatment who survived for 20 years"],"prefix":"10.3324","volume":"109","author":[{"given":"Alenka Djarmila","family":"Behsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esten Nymoen","family":"Vandsemb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias Schmidt","family":"Sl\u00f8rdahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Hjorth-Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petter","family":"Quist-Paulsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine","family":"Misund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marit","family":"Sponaas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Waage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,10,5]]},"reference":[{"key":"60042","doi-asserted-by":"crossref","unstructured":"Pessoa de Magalhaes RJ, Vidriales MB, Paiva B. Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry. Haematologica. 2013; 98(1):79-86.","DOI":"10.3324\/haematol.2012.067272"},{"key":"60043","doi-asserted-by":"crossref","unstructured":"Langseth OO, Myklebust TA, Johannesen TB, Hjertner O, Waage A. Incidence and survival of multiple myeloma: a population-based study of 10,524 patients diagnosed 1982-2017. Br J Haematol. 2020; 191(3):418-425.","DOI":"10.1111\/bjh.16674"},{"key":"60044","doi-asserted-by":"crossref","unstructured":"Zavidij O, Haradhvala NJ, Mouhieddine TH. Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. Nat Cancer. 2020; 1(5):493-506.","DOI":"10.1038\/s43018-020-0053-3"},{"key":"60045","doi-asserted-by":"crossref","unstructured":"Bailur JK, McCachren SS, Doxie DB. Early alterations in stem-like\/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy. JCI Insight. 2019; 5(11):e127807.","DOI":"10.1172\/jci.insight.127807"},{"key":"60046","doi-asserted-by":"crossref","unstructured":"Misund K, Hofste Op Bruinink D, Coward E. Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence. Leukemia. 2022; 36(7):1887-1897.","DOI":"10.1038\/s41375-022-01597-y"},{"key":"60047","doi-asserted-by":"crossref","unstructured":"Zelle-Rieser C, Thangavadivel S, Biedermann R. T cells in multiple myeloma display features of exhaustion and senescence at the tumor site. J Hematol Oncol. 2016; 9(1):116.","DOI":"10.1186\/s13045-016-0345-3"},{"key":"60048","doi-asserted-by":"crossref","unstructured":"Costa LJ, Chhabra S, Medvedova E. Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma. J Clin Oncol. 2022; 40(25):2901-2912.","DOI":"10.1200\/JCO.21.01935"},{"key":"60049","doi-asserted-by":"crossref","unstructured":"Mahon FX, Rea D, Guilhot J. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010; 11(11):1029-1035.","DOI":"10.1016\/S1470-2045(10)70233-3"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283563\/76164","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283563\/76824","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11294\/76164","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:05:00Z","timestamp":1794045900000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.283563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,5]]},"references-count":8,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,3,31]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.283563","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,5]]}}}